MX2022005628A - Regimen de dosificacion para agentes anti-bcma. - Google Patents

Regimen de dosificacion para agentes anti-bcma.

Info

Publication number
MX2022005628A
MX2022005628A MX2022005628A MX2022005628A MX2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A
Authority
MX
Mexico
Prior art keywords
bcma
antibody construct
treatment
agents
domain
Prior art date
Application number
MX2022005628A
Other languages
English (en)
Inventor
Julia Stieglmaier
Birgit Huber
Alexander Minella
Vijay Upreti
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68581157&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022005628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of MX2022005628A publication Critical patent/MX2022005628A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a la dosificación y administración de agentes anti-BCMA para el tratamiento de neoplasias positivas para BCMA. Más específicamente, la presente invención se refiere a una construcción de anticuerpo que comprende un primer dominio que se une a BCMA, un segundo dominio que se une a CD3 y un tercer dominio que se extiende o mejora la semivida de la construcción de anticuerpo, para su uso en el tratamiento o mejora de una neoplasia positiva para BCMA, en donde la construcción de anticuerpo se administra a una dosis especifica en al menos un ciclo. Además, la invención se refiere a un método pare el tratamiento de una neoplasia positiva para BCMA que comprende la administración de una dosis específica de dicha construcción de anticuerpo y el uso de dicha construcción de anticuerpo para la fabricación de un medicamento para el tratamiento de una neoplasia positiva para BCMA.
MX2022005628A 2019-11-11 2020-05-08 Regimen de dosificacion para agentes anti-bcma. MX2022005628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208417.6A EP3819007A1 (en) 2019-11-11 2019-11-11 Dosing regimen for anti-bcma agents
PCT/EP2020/062876 WO2021094000A1 (en) 2019-11-11 2020-05-08 Dosing regimen for anti-bcma agents

Publications (1)

Publication Number Publication Date
MX2022005628A true MX2022005628A (es) 2022-06-14

Family

ID=68581157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005628A MX2022005628A (es) 2019-11-11 2020-05-08 Regimen de dosificacion para agentes anti-bcma.

Country Status (10)

Country Link
US (1) US20210139584A1 (es)
EP (2) EP3819007A1 (es)
JP (1) JP2022554362A (es)
AU (1) AU2020381671A1 (es)
CA (1) CA3155069A1 (es)
DK (1) DK4058148T3 (es)
FI (1) FI4058148T3 (es)
MX (1) MX2022005628A (es)
TW (1) TW202118784A (es)
WO (1) WO2021094000A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4243936A1 (en) * 2020-11-10 2023-09-20 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
WO2023098846A1 (zh) * 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
ATE251181T1 (de) 1998-07-28 2003-10-15 Micromet Ag Heterominikörper
SI1673398T1 (sl) 2003-10-16 2011-05-31 Micromet Ag Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
ES2432792T5 (es) 2007-04-03 2023-01-16 Amgen Res Munich Gmbh Dominio de unión a CD3-épsilon específico de especies cruzadas
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
WO2010037838A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
CN103347893A (zh) 2010-11-01 2013-10-09 诺维信生物制药丹麦公司 白蛋白变体
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
JP6430828B2 (ja) 2011-05-05 2018-11-28 アルブミディクス リミティド アルブミン変異体
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP3892640A1 (en) 2011-08-23 2021-10-13 Roche Glycart AG Bispecific t cell activating antigen binding molecules
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CA2861592A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
MX357011B (es) 2013-03-15 2018-06-22 Amgen Inc Anticuerpos biespecificos heterodimericos.
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP3733710A1 (en) 2013-09-25 2020-11-04 Amgen, Inc Hetrodimeric v-c-fc-v-c antibody
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
KR20210068408A (ko) * 2018-09-28 2021-06-09 암젠 인크 가용성 bcma에 대한 항체
WO2020150702A1 (en) * 2019-01-18 2020-07-23 University Of Southern California Methods and compositions to improve the safety and efficacy of cellular therapies

Also Published As

Publication number Publication date
FI4058148T3 (fi) 2024-05-06
US20210139584A1 (en) 2021-05-13
AU2020381671A1 (en) 2022-03-31
TW202118784A (zh) 2021-05-16
EP4058148B1 (en) 2024-03-13
WO2021094000A1 (en) 2021-05-20
JP2022554362A (ja) 2022-12-28
EP4058148A1 (en) 2022-09-21
EP3819007A1 (en) 2021-05-12
DK4058148T3 (da) 2024-05-06
CA3155069A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
JP2018522850A5 (es)
RU2017134443A (ru) Способ лечения с применением традипитанта
EA201690738A1 (ru) Ингалятор сухого порошка
PA8635501A1 (es) Uso de un anticuerpo para el tratamiento del lupus
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
JP2016518387A5 (es)
MX2019005623A (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
JP2017160178A5 (es)
MX2022005628A (es) Regimen de dosificacion para agentes anti-bcma.
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
EA201000127A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
JP2016512564A5 (es)
HRP20240022T1 (hr) Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem
JP2014511383A5 (es)
RU2018127640A (ru) Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников
AR104771A1 (es) Inhalador de polvo seco
JP2017502016A5 (es)
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
JP2013541587A5 (es)
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
CY1120176T1 (el) Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.